Development asset linked to UroGen Pharma in public FDA and regional records.
pharma · Spinal Cord Injury · Neurological; Disorder, Nervous System
UroGen Pharma
EuroGen Pharmaceuticals Ltd
UroGen Pharma drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Princeton, USA HQ
2004 Founded
322 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Princeton, USA
- Founded
- 2004
- Employees
- 322
- Programs
- 2
- Drugs
- 5
- Patents
- 0
UroGen Pharma pipeline
Portfolio lens on 5 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
UroGen Pharma drug portfolio — 5 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
ex vivo expanded autologous human corneal epithelial cells containing stem cells
Sensory organs (S01)Sensory organs (S01) compound in UroGen Pharma's portfolio. Mechanism: Somatic cell supplemental therapy.
- Mechanism
- Somatic cell supplemental therapy
-
Development asset linked to UroGen Pharma in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Diagnostic agent.
- Mechanism
- Diagnostic agent
-
Development asset linked to UroGen Pharma in public FDA and regional records.